Detalhe da pesquisa
1.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Artigo
Inglês
| MEDLINE | ID: mdl-37369099
2.
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
Cancer
; 127(22): 4190-4197, 2021 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34343354
3.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34407608
4.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34196165
5.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32511983
6.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leuk Lymphoma
; 62(14): 3440-3451, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34414843
7.
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 2(4): e117, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26185773